| Private Placement / Financing Transactions
Neuralink: The company raised $650 million of Series E venture funding from G42, Lightspeed Commerce, and Valor Equity Partners on May 27, 2025, putting the company’s pre-money valuation at $8.4 billion. SaxeCap, 1802 Ventures, Neman Ventures, DFJ Growth, Vy Capital, Founders Fund, Bossa Invest, Axevil Capital, Human Capital, Sequoia Capital, Thrive Capital, Qatar Investment Authority, and ARK Investment Management also participated in the round. The company is a developer of an implantable brain-machine interface designed to help people with paralysis.
Jane: The company closed on $500 million of an undisclosed targeted amount of venture funding in a deal led by TCV on May 26, 2025, putting the company’s pre-money valuation at $1.3 billion. JMI Equity and Tidemark also participated in the round. The company is a developer of a health and wellness practice management platform designed to support clinics of various types and sizes with administrative and clinical workflows.
GRIN Therapeutics: The company raised $140 million of Series D venture funding from Angelini Pharma and Blackstone on May 27, 2025. The company is an operator of a biopharmaceutical business intended to develop precision therapies for pediatric neurodevelopmental disorders caused by mutations in the GRIN genes.
GlycoEra: The company raised $130 million of Series B venture funding in a deal led by Novo Holdings on May 27, 2025. MP Healthcare Venture Management, Sixty Degree Capital, Roche Ventures, Agent Capital, 5AM Ventures, Sofinnova Partners, Catalio Capital Management, LifeArc Ventures, Qatar Investment Authority, and Bristol-Myers Squibb Foundation also participated in the round. The company is an operator of a biotechnology business dedicated to developing protein degraders to transform the treatment of autoimmune diseases.
Syndeio Biosciences: The company raised $90 million of venture funding from Innoviva, Tenmile and Luson BioVentures on May 27, 2025. Evolution VC Partners, Palo Santo and Catalio Capital Management also participated in the round. The company is an operator of a synapse-focused biotech business intended to pioneer a new class of therapies for neuropsychiatric and cognitive disorders.
Vima Therapeutics: The company raised $60 million of Series A venture funding in a deal led by Atlas Venture on May 29, 2025. Access Biotechnology and Canaan also participated in the round. The company is a developer of oral therapeutics designed for the treatment of dystonia and related movement disorders.
Vivodyne: The company raised $40 million of Series A venture funding in a deal led by Khosla Ventures on May 29, 2025, putting the company’s pre-money valuation at $134 million. Helena Special Investments and other undisclosed investors also participated in the round. The company is a developer of a preclinical drug testing platform designed to accelerate the discovery of cures for human diseases with highly scalable drug testing on lab-grown 3D human tissues.
Pillar Biosciences: The company raised $34.5 million of venture funding from Illumina and Soleus Capital on May 27, 2025. The company is a developer of a sequencing platform designed to support treatment selection through accurate testing across different stages of cancer care.
Outcomes4me: The company raised $21 million of venture funding from Labcorp Venture Fund, Salica Investments and Forecast Labs on May 29, 2025. Asset Management Ventures, Sierra Ventures, Merstal, Northpond Ventures and IRA Capital also participated in the round. The company is a developer of an AI-powered digital platform designed to assist cancer patients in managing their care.
Diakonos Oncology: The company raised $20 million of venture funding from The Brain Tumor Investment Fund, Buttonwood Titan QC Fund and Baylor College Of Medicine on May 30, 2025 in the form of SAFE notes. The company is an operator of an immunotherapy clinical trials research business developing a Dendritic Cell Vaccine (DCV) for difficult-to-treat cancers.
Hedera Dx: The company raised EUR 15 million of Series A venture funding in a deal led by VSquared Ventures on May 27, 2025. Helsana HealthInvest, Inventure, Top Harvest Capital, Eyrir Venture Management and Tesi also participated in the round. The company is an operator of an oncology research business focused on developing liquid biopsy solutions that improve patient experiences and outcomes.
Sortera Bio: The company is in the process of raising GBP 10 million of venture funding on May 29, 2025. The company is an operator of a biologics discovery platform intended to accelerate drug development through Artificial Intelligence powered screening technology.
ProteinQure: The company raised $11 million of Series A venture funding from undisclosed investors on May 27, 2025. The company is an operator of a biotech business focused on the design of novel exotic peptides with broad therapeutic applications.
C2N Diagnostics: The company raised $10 million of venture funding from undisclosed investors on May 29, 2025. The company is a provider of specialty diagnostic testing services intended to offer novel diagnostics for Alzheimer’s disease.
Blinktbi: The company raised $6.2 million of Series C venture funding from undisclosed investors on May 29, 2025, putting the company’s pre-money valuation at $44 million. The company is a developer of a blink reflex assessment technology designed to improve the detection, differentiation and management of neurological diseases.
Maxiom Labs: The company is in the process of raising $6 million of Series A venture funding as of May 27, 2025. The company is a developer of an artificial intelligence-driven meta-analyses platform intended to optimize health, fitness, and performance for athletes.
Accelus: The company raised venture funding in a deal led by Concord Health Partners on May 29, 2025. Other undisclosed investors also participated in the round. The company is a developer of medical implants designed to focus on expandable interbody technology for spine surgery.
Alantos Pharmaceuticals Holding: The company received an undisclosed amount of development capital from Industrial Innovation Partners in approximately June 2025. The company is a developer of drugs intended for the treatment of diabetes and inflammatory diseases.
Cayuga Biotech: The company raised an undisclosed amount of venture funding from SideCar Angels in approximately June 2025. The company is a developer of biomimetic therapeutics designed to address haemorrhage and bleeding disorders.
Curve Biosciences: The company raised an undisclosed amount of venture funding from First Spark Ventures in June 2025. The company is a developer of liver cancer diagnostics designed for disease prevention and screening.
Exo: The company is in the process of raising Series D venture funding in a deal led by Sands Capital, Qubit Health Capital and BOLD Capital Partners on May 27, 2025. Samsung Venture Investment and other undisclosed investors are also participating in the round. The company is a developer of a handheld ultrasound device designed for medical imaging and therapeutic applications.
InformAI: The company raised an undisclosed amount of venture funding from Texas Medical Center in June 2025. The company is a developer of medical data analytics software designed to improve patient outcomes and operational functions and enable large dataset synthesis in clinical care.
Nerai Bio: The company raised an undisclosed amount of venture funding from Kickfund on May 26, 2025. The company is an operator of a biotechnology business intended to focus on developing novel, personalized gene-editing tools to treat diseases currently beyond the reach of existing therapies.
Veyond Metaverse: The company raised venture funding on May 28, 2025. The company is a developer of an immersive mixed-reality technology designed to improve medical education, surgical training and diagnosis.
|
